药品注册申请号:200678
申请类型:NDA (新药申请)
申请人:ASTRAZENECA AB
申请人全名:ASTRAZENECA AB
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 500MG;EQ 5MG BASE Yes No AB 2010/11/05 2010/11/05 Discontinued
002 KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 5MG BASE Yes No AB 2010/11/05 Discontinued
003 KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 2.5MG BASE Yes No AB 2010/11/05 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/10/11 SUPPL-28(补充) Approval Efficacy STANDARD
2019/07/01 SUPPL-24(补充) Approval Labeling 901 REQUIRED
2017/02/27 SUPPL-18(补充) Approval Efficacy STANDARD
2017/01/18 SUPPL-20(补充) Approval Labeling STANDARD
2017/01/18 SUPPL-19(补充) Approval Labeling 901 REQUIRED
2016/04/05 SUPPL-13(补充) Approval Efficacy STANDARD
2015/08/28 SUPPL-16(补充) Approval Labeling 901 REQUIRED
2015/02/09 SUPPL-14(补充) Approval Manufacturing (CMC) STANDARD
2013/05/24 SUPPL-10(补充) Approval Efficacy STANDARD
2013/05/15 SUPPL-2(补充) Approval Manufacturing (CMC) STANDARD
2012/11/08 SUPPL-9(补充) Approval Manufacturing (CMC) STANDARD
2012/04/01 SUPPL-7(补充) Approval Labeling UNKNOWN
2012/03/07 SUPPL-4(补充) Approval Efficacy STANDARD
2012/03/07 SUPPL-3(补充) Approval Efficacy STANDARD
2011/11/15 SUPPL-5(补充) Approval Labeling UNKNOWN
2010/11/05 ORIG-1(原始申请) Approval Type 4 - New Combination STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 8628799 2025/07/13 Y 2014/01/31 PDF格式
9339472 2025/07/13 Y 2016/05/26 PDF格式
002 8628799 2025/07/13 Y 2017/03/22 PDF格式
9339472 2025/07/13 Y 2017/03/22 PDF格式
003 8628799 2025/07/13 Y 2017/03/22 PDF格式
9339472 2025/07/13 Y 2017/03/22 PDF格式
001 RE44186 2023/07/31 Y Y U-1838 U-1097 PDF格式**本条是由Drugfuture回溯的历史信息**
002 RE44186 2023/07/31 Y Y U-1838 U-1097 PDF格式**本条是由Drugfuture回溯的历史信息**
003 RE44186 2023/07/31 Y Y U-1097 U-1838 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 M-134 2016/05/24**本条是由Drugfuture回溯的历史信息**
M-175 2019/04/05**本条是由Drugfuture回溯的历史信息**
M-198 2020/02/27**本条是由Drugfuture回溯的历史信息**
NCE 2014/07/31**本条是由Drugfuture回溯的历史信息**
002 M-134 2016/05/24**本条是由Drugfuture回溯的历史信息**
M-175 2019/04/05**本条是由Drugfuture回溯的历史信息**
M-198 2020/02/27**本条是由Drugfuture回溯的历史信息**
NCE 2014/07/31**本条是由Drugfuture回溯的历史信息**
003 M-134 2016/05/24**本条是由Drugfuture回溯的历史信息**
M-175 2019/04/05**本条是由Drugfuture回溯的历史信息**
M-198 2020/02/27**本条是由Drugfuture回溯的历史信息**
NCE 2014/07/31**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:500MG;EQ 5MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
200678 001 NDA KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 500MG;EQ 5MG BASE Discontinued Yes No AB 2010/11/05 ASTRAZENECA AB
205981 001 ANDA SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 500MG;EQ 5MG BASE Prescription No No AB 2023/07/31 MYLAN
206081 001 ANDA SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 500MG;EQ 5MG BASE Prescription No No AB 2023/07/31 SUN PHARM
207678 001 ANDA METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 500MG;EQ 5MG BASE Prescription No No AB 2023/08/09 DR REDDYS LABS SA
活性成分:METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:1GM;EQ 5MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
200678 002 NDA KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 5MG BASE Discontinued Yes No AB 2010/11/05 ASTRAZENECA AB
205981 003 ANDA SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 5MG BASE Prescription No No AB 2023/07/31 MYLAN
206081 003 ANDA SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 5MG BASE Prescription No No AB 2023/07/31 SUN PHARM
207678 003 ANDA METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 5MG BASE Prescription No Yes AB 2023/08/09 DR REDDYS LABS SA
活性成分:METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:1GM;EQ 2.5MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
200678 003 NDA KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 2.5MG BASE Discontinued Yes No AB 2010/11/05 ASTRAZENECA AB
205981 002 ANDA SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 2.5MG BASE Prescription No No AB 2023/07/31 MYLAN
206081 002 ANDA SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 2.5MG BASE Prescription No No AB 2023/07/31 SUN PHARM
207678 002 ANDA METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL 1GM;EQ 2.5MG BASE Prescription No No AB 2023/08/09 DR REDDYS LABS SA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database